Is Brown & Brown (BRO) A Bargain After Its 90 Day Rebound?

Brown & Brown stock performance snapshot after recent moves

Brown & Brown (BRO) has seen mixed recent trading, with the stock down about 1.6% over the past day and 2.6% over the past week, while edging slightly higher over the past month.

At a share price of $71.42, Brown & Brown has given investors a strong 90 day share price return of about 21%, although the year to date share price return is down around 8% and the 1 year total shareholder return has declined roughly 24%. This suggests that recent momentum has picked up after a weaker stretch for long term holders.

Compare Brown & Brown's recent swings with a hand picked 82 resilient stocks with low risk scores that have held up more steadily through similar market moves.

After a sharp 90 day rebound yet weaker returns over 1 and 3 years, investors in Brown & Brown now face a simple tension. Has most of the upside already played out, or does current pricing still leave room ahead?

Most Popular Narrative: 5.6% Undervalued

Brown & Brown's most followed narrative points to a fair value of about $75.63 per share versus the last close at $71.42. This frames the current debate about whether recent price strength has fully reflected the underlying story.

Strong cash flow from operations, combined with a strategic focus on leveraging a diversified portfolio across geographies and lines of business, positions the company to navigate economic uncertainties and potentially increase future earnings stability and growth.

Read the complete narrative. Read the complete narrative.

The fair value hinges on a clear set of assumptions: revenue growth that is steady rather than rapid, margins that ease but remain solid, and a future earnings multiple that requires real confidence in Brown & Brown's cash generation and business mix.

Result: Fair Value of $75.63 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Brown & Brown's narrative could be challenged if tariffs, inflation or interest rates curb client activity, or if rising pharmacy costs squeeze benefits-related margins.

Find out about the key risks to this Brown & Brown narrative.

Another view on Brown & Brown’s valuation

The earlier fair value of $75.63 paints Brown & Brown as 5.6% undervalued. However, the P/E lens tells a different story. The stock trades on 20.1x earnings, which is higher than both the US Insurance industry at 11.6x and its own fair ratio of 12.6x. That points to a richer price that the market could eventually adjust toward. Is this a temporary premium or a sign that earnings expectations need to be revisited?

To see how this valuation gap looks through earnings based ratios in detail, take a closer look at our valuation breakdown for Brown & Brown, then compare it with a broader set of peers using the same framework. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Brown & Brown clearly mixed, now is the moment to look through the data yourself and weigh both sides carefully. To see the full balance of potential upsides and downsides before you act, start with these 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Brown & Brown?

If Brown & Brown has your attention, do not stop there. The market will keep moving whether you look for fresh ideas or not, so give yourself options.

• Spot potential value opportunities early by scanning a curated 19 high quality undiscovered gems that many investors may be overlooking.
• Strengthen your downside protection by reviewing a focused list of solid balance sheet and fundamentals (52 results) that can help you stress test your portfolio.
• Target resilient price action by checking a carefully filtered 82 resilient stocks with low risk scores that aims to smooth out the bumps in volatile markets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com